Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-04-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
关于第二期员工持股计划展期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the duration of the company's second employee stock ownership plan. It includes details about the plan's approval, stock purchase, and extension period. The document is relatively short (1135 characters) and serves as a formal announcement to shareholders and the public about this specific corporate action. It does not contain financial statements, audit information, or detailed management discussion. It is not a report or presentation but an official announcement about a capital-related plan (employee stock ownership plan). Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP), as it relates to company financing activities and capital structure changes through employee stock plans.
2020-04-24 Chinese
第七届监事会第8次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company, detailing the approval of various reports and proposals including the 2019 Annual Report, 2019 financial statements, profit distribution plan, internal control evaluation, and the 2020 Q1 report. It includes voting results on these items but does not contain the full reports themselves. The document is relatively short (2388 characters) and serves as an official announcement of the Supervisory Board's decisions and approvals rather than the full financial reports. Therefore, it fits best as a Regulatory Filing (RNS) since it is an official regulatory announcement about approvals and resolutions related to reports, not the reports themselves.
2020-04-24 Chinese
2019年度审计委员会述职报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度审计委员会述职报告' which translates to '2019 Annual Audit Committee Work Report'. It details the audit committee's activities, including supervision of external and internal audits, evaluation of internal controls, and review of financial statements for the year 2019. It references audit plans, audit reports, and internal control audit reports, but it is not the audit report itself. Instead, it is a report from the audit committee to the board summarizing their oversight and work during the year. The document is relatively short (1447 characters) and focuses on audit committee activities rather than presenting full financial statements or audit opinions. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports, excluding full annual reports. FY 2019
2020-04-24 Chinese
国信证券股份有限公司关于天士力医药集团股份有限公司2019年度募集资金存放与使用专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2019年度募集资金存放与使用专项核查报告" which translates to "2019 Annual Special Inspection Report on the Deposit and Use of Raised Funds." It is prepared by the sponsor (Guosen Securities) for the company Tianshili Pharmaceutical Group Co., Ltd. The content includes detailed information about the management, storage, and use of raised funds, compliance with regulatory requirements, and includes an auditor's verification opinion. The document is a specialized audit or verification report focusing on the use of raised funds, not a full annual report or earnings release. It is not a simple announcement or publication notice but contains substantive audit and verification content. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (6468 characters) supports it being a full report rather than a brief announcement. FY 2019
2020-04-24 Chinese
2019年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2019. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. The document is relatively short (1065 characters) and focuses solely on the audit of internal controls rather than presenting full financial statements or comprehensive annual report content. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the correct classification is AR with high confidence.
2020-04-24 Chinese
独立董事2019年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors 2019 Annual Work Report" for a company, detailing the independent directors' activities, attendance at board meetings, opinions on various company matters including financial audits, internal controls, profit distribution, related party transactions, and employee stock plans. It includes detailed descriptions of the independent directors' roles, their compliance with laws and regulations, and their oversight of the company's governance and financial reporting processes for the year 2019. The content is a formal report by the independent directors on their duties and observations for the year, which aligns with a Management Report or similar detailed governance and oversight report. It is not a full Annual Report (10-K), nor is it an Audit Report (AR) or a simple announcement. It is not a proxy statement or voting results. The document is comprehensive and substantive, focusing on management and board oversight activities and opinions, which fits best under Board/Management Information (MANG).
2020-04-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.